Skip to main content

Table 3 Association of antiplatelet medications and risk of death

From: Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma

 

HR 95% CI

p-value

Antiplatelet

No

Yes

 

Unadjusted

1.0

0.73 (0.58-0.92)

0.0008

Adjusted*

1.0

0.76 (0.58-0.99)

0.04

Antiplatelet medications in 5 categories of platelet counts

Low

1.0

1.74 (0.74-4.09)

0.20

Low Normal

1.0

0.88 (0.55-1.42)

0.58

Mid Normal

1.0

0.68 (0.42-1.11)

0.12

High normal

1.0

0.87(0.48-1.51)

0.64

High

1.0

0.42 (0.17-1.05)

0.06

  1. *Adjusted for age, race, tumor site, grade, treatment, platelet count and smoking.